- ►diabetesjournals.org M St John Sutton, M Rendell, P Dandona, JF Dole, … - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Of the 203 patients randomly assigned to RSG (4 mg
bid) or glyburide (GLB) (titrated to achieve optimal glycemic control for the first 8 weeks only to
limit the risk of hypoglycemia; mean 10.5 mg/day), 118 had an echocardiogram ... Cited by 219 - Related articles - BL Direct - All 5 versions
- ►onlinejacc.org WHW Tang, GS Francis, BJ Hoogwerf, JB Young - Journal of the American …, 2003 - Elsevier We examined 111 consecutive diabetic patients with chronic systolic HF who were treated with
TZD from January 1999 to June 2001. A retrospective chart review was performed to determine
the incidence of fluid retention in this cohort. Physical signs of fluid retention were ... Cited by 122 - Related articles - BL Direct - All 16 versions
SMA Bennett, A Agrawal, H Elasha, M Heise, … - Diabetic …, 2004 - interscience.wiley.com Methods Eighteen subjects with persistent IGT were randomized to receive rosiglitazone 4 mg
twice daily or matching placebo for 12 weeks. Evaluation at baseline and at the end of treatment
included measurement of whole body insulin sensitivity during a euglycaemic ... Cited by 69 - Related articles - BL Direct - All 4 versions
AJ Karter, AT Ahmed, J Liu, HH Moffet, MM … - Diabetic …, 2005 - interscience.wiley.com Methods A cohort study of all patients in the Kaiser Permanente Medical Care Program with Type
2 diabetes (Kaiser Permanente Northern California Diabetes Registry) who initiated any diabetes
pharmacotherapy (n = 23 440) between October 1999 and November 2001. Only patients ... Cited by 69 - Related articles - BL Direct - All 4 versions
P Raskin, M Rendell, MC Riddle, JF Dole, MI Freed, … - Diabetes Care, 2001 - Am Diabetes Assoc RESULTS—RSG 4 and 8 mg daily significantly improved glycemic control, which was unchanged
on PBO. By intent-to-treat analysis, treatment with RSG 8 mg plus insulin resulted in a mean
reduction from baseline in HbA 1c of 1.2% (P < 0.0001), despite a 12% mean reduction of ... Cited by 242 - Related articles - BL Direct - All 7 versions
- ►ahajournals.org FA Masoudi, SE Inzucchi, Y Wang, EP Havranek, JAM … - Circulation, 2005 - Am Heart Assoc Methods and Results— We conducted a retrospective cohort study of 16 417 Medicare beneficiaries
with diabetes discharged after hospitalization with the principal discharge diagnosis of heart
failure. The association between antidiabetic drug prescriptions and outcomes was ... Cited by 195 - Related articles - All 10 versions
- ►onlinejacc.org HJ Dargie, PR Hildebrandt, GAJ Riegger, JJV … - Journal of the American …, 2007 - Elsevier This study investigated the effects of rosiglitazone (RSG) on left ventricular ejection fraction
(LVEF) in subjects with type 2 diabetes (T2DM) and pre-existing chronic heart failure (CHF)
(New York Heart Association [NYHA] functional class I to II). ... Fluid retention is an ... Cited by 88 - Related articles - BL Direct - All 13 versions
G Bakris, G Viberti, WM Weston, M Heise, LE … - Journal of human …, 2003 - nature.com This study examines the effect of rosiglitazone on urinary albumin excretion (UAE) in patients
with type II diabetes. Urinary albumin: creatinine ratio (ACR) was measured in a 52-week,
open-label, cardiac safety study comparing rosiglitazone and glyburide. Patients were ... Cited by 241 - Related articles - BL Direct - All 3 versions
RW Nesto, D Bell, RO Bonow, V Fonseca, SM Grundy, … - Circulation, 2003 - Am Heart Assoc These beneficial effects of TZDs on glycemia and cardiovascular risk factors have made them
attractive agents in patients with type 2 diabetes who are at high risk for CVD. There is a growing
recognition, however, that edema can occur in patients treated with either drug. Because ... Cited by 575 - Related articles - BL Direct - All 17 versions
- ►endojournals.org HE Lebovitz, JF Dole, R Patwardhan, EB … - Journal of Clinical …, 2001 - Endocrine Soc This study evaluated the efficacy and safety of rosiglitazone monotherapy in patients with type
2 diabetes. After a 4-week placebo run-in period, 493 patients with type 2 diabetes were randomized
to receive rosiglitazone [2 or 4 mg twice daily (bd)] or placebo for 26 weeks. The primary ... Cited by 415 - Related articles - BL Direct - All 5 versions
